This content is machine translated Conference on Retroviruses and Opportunistic Infections (CROI 2022) Five-year data of single-tablet regimen B/F/TAF published. At the 29th CROI, Gilead Sciences presented five-year data from two Phase 3 studies (Study 1489 and Study 1490) that evaluated use in untreated individuals living with HIV. The results…
